Viridian Therapeutics (VRDN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Viridian Therapeutics Revenue Highlights

Latest Revenue (Y)

$314.00K

Latest Revenue (Q)

$86.00K

Main Segment (Y)

Collaboration Revenue

Viridian Therapeutics Revenue by Period

Viridian Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$314.00K	-82.28%
2022-12-31	$1.77M	-40.20%
2021-12-31	$2.96M	182.19%
2020-12-31	$1.05M	-76.46%
2019-12-31	$4.46M	-46.80%
2018-12-31	$8.39M	109.49%
2017-12-31	$4.00M	19.96%
2016-12-31	$3.34M	31.48%
2015-12-31	$2.54M	-41.25%
2014-12-31	$4.32M	0.08%
2013-12-31	$4.32M	-2.03%
2012-12-31	$4.41M	-

Viridian Therapeutics generated $314.00K in revenue during NA 2023, up -82.28% compared to the previous quarter, and up 3.74% compared to the same period a year ago.

Viridian Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$86.00K	19.44%
2024-06-30	$72.00K	-
2024-03-31	$72.00K	-
2023-12-31	$72.00K	-
2023-09-30	$72.00K	-
2023-06-30	$72.00K	-26.53%
2023-03-31	$98.00K	-6.67%
2022-12-31	$105.00K	-91.21%
2022-09-30	$1.20M	366.80%
2022-06-30	$256.00K	18.52%
2022-03-31	$216.00K	0.93%
2021-12-31	$214.00K	2.88%
2021-09-30	$208.00K	-80.92%
2021-06-30	$1.09M	-24.88%
2021-03-31	$1.45M	2587.04%
2020-12-31	$54.00K	100.00%
2020-09-30	-	-100.00%
2020-06-30	$168.00K	-79.71%
2020-03-31	$828.00K	-5.91%
2019-12-31	$880.00K	26.62%
2019-09-30	$695.00K	-72.35%
2019-06-30	$2.51M	575.81%
2019-03-31	$372.00K	-21.85%
2018-12-31	$476.00K	-49.58%
2018-09-30	$944.00K	-56.74%
2018-06-30	$2.18M	-54.39%
2018-03-31	$4.78M	301.34%
2017-12-31	$1.19M	-26.92%
2017-09-30	$1.63M	127.16%
2017-06-30	$718.00K	55.41%
2017-03-31	$462.00K	-38.89%
2016-12-31	$756.00K	-14.96%
2016-09-30	$889.00K	1.72%
2016-06-30	$874.00K	6.85%
2016-03-31	$818.00K	24.13%
2015-12-31	$659.00K	31.54%
2015-09-30	$501.00K	-31.74%
2015-06-30	$734.00K	13.80%
2015-03-31	$645.00K	-1.45%
2014-12-31	$654.52K	-49.69%
2014-09-30	$1.30M	2.15%
2014-06-30	$1.27M	16.74%
2014-03-31	$1.09M	0.03%
2013-12-31	$1.09M	10.88%
2013-09-30	$983.59K	-10.82%
2013-06-30	$1.10M	-3.20%
2013-03-31	$1.14M	-

Viridian Therapeutics generated $86.00K in revenue during Q3 2024, up 19.44% compared to the previous quarter, and up 119.44% compared to the same period a year ago.

Viridian Therapeutics Revenue Breakdown

Viridian Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Collaboration Revenue	$300.00K	$1.80M	$2.96M	$735.00K	-
Grant	-	-	-	$315.00K	-
Milestone Payments	-	-	-	-	-

Viridian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Collaboration Revenue	$100.00K	$100.00K	-	$100.00K	$100.00K	$100.00K	$100.00K	$1.20M	$300.00K	$200.00K	$208.00K	-	-	$54.00K	-	$837.00K	$625.00K	$2.50M	-	-
Grant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$168.00K	$43.00K	$70.00K	$16.00K	-	-
Collaboration Revenue, Related Party	-	-	-	-	-	-	-	-	-	-	-	$1.09M	$1.45M	-	-	-	-	-	-	-
Reimbursement Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$700.00K	$837.00K	$625.00K	$2.50M	-
Milestone Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Viridian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration Revenue (100.00%).

Viridian Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BPMC	Blueprint Medicines	$249.38M	$128.18M
ACLX	Arcellx	$110.32M	$26.03M
PTGX	Protagonist Therapeutics	$60.00M	$4.67M
MRUS	Merus	$43.95M	$11.77M
RVMD	Revolution Medicines, Inc. Warrant	$11.58M	-
CYTK	Cytokinetics	$7.53M	$463.00K
CRNX	Crinetics Pharmaceuticals	$4.01M	-
PLRX	Pliant Therapeutics	$1.58M	-
VRDN	Viridian Therapeutics	$314.00K	$86.00K
GPCR	Structure Therapeutics	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
DICE	DICE Therapeutics	-	-
INZY	Inozyme Pharma	-	-
CERE	Cerevel Therapeutics	-	-
REPL	Replimune Group	-	-
KURA	Kura Oncology	-	-
SNDX	Syndax Pharmaceuticals	-	$12.50M
TERN	Terns Pharmaceuticals	-	-
ETNB	89bio	-	-

VRDN Revenue FAQ

What is Viridian Therapeutics’s yearly revenue?

Viridian Therapeutics's yearly revenue for 2023 was $314K, representing a decrease of -82.28% compared to 2022. The company's yearly revenue for 2022 was $1.77M, representing a decrease of -40.20% compared to 2021. VRDN's yearly revenue for 2021 was $2.96M, representing an increase of 182.19% compared to 2020.

What is Viridian Therapeutics’s quarterly revenue?

Viridian Therapeutics's quarterly revenue for Q3 2024 was $86K, a 19.44% increase from the previous quarter (Q2 2024), and a 19.44% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $72K, a 0% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). VRDN's quarterly revenue for Q1 2024 was $72K, a 0% increase from the previous quarter (Q4 2023), and a -26.53% decrease year-over-year (Q1 2023).

What is Viridian Therapeutics’s revenue growth rate?

Viridian Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -89.40%, and for the last 5 years (2019-2023) was -92.96%.

What are Viridian Therapeutics’s revenue streams?

Viridian Therapeutics's revenue streams in c 23 are Collaboration Revenue

What is Viridian Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Viridian Therapeutics was Collaboration Revenue. This segment made a revenue of $300K, representing 100.00% of the company's total revenue.